CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 90 enrolled
Drug / intervention
Lebrikizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05372419
NCT05372419Phase 3Completed
CompareCT.gov

An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Eli Lilly and Company·interventional·Posted May 12, 2022·Updated Mar 9, 2026

In Brief

A Phase 3 clinical trial evaluating Lebrikizumab for Atopic Dermatitis. Completed, enrolled 90 participants across 36 sites.

Detailed Summary

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMay 12, 2022
Enrollment StartJan 12, 2023
Primary CompletionMay 3, 2024
Study CompletionFeb 17, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.1 years ago

Interventions

Lebrikizumabdrug

Administered SC